ADMA Biologics, Inc.
ADMA Biologics, Inc. (ADMA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ADMA · as of Sep 30, 2025
Ownership Breakdown
384
Institutional Holders
▼ 3 vs Q2
$3.28B
Total Inst. Value
▼ $564.01M vs Q2
231.77M
Shares Outstanding
freeFloat 97.82%
219.35M
13F Shares Held
▲ 8.22M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ADMA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 35.63M | 14.75% | 14.75% | $522.36B | Nov 12, 2025 | ▼ 841.7K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 20.97M | 8.69% | 8.69% | $307.49B | Nov 7, 2025 | ▼ 388.7K |
STATE STREET CORP biological products, (no diagnostic substances) | 13.56M | 5.62% | 5.62% | $198.81B | Nov 14, 2025 | ▲ 1.48M |
INVESCO LTD. biological products, (no diagnostic substances) | 12.51M | 5.18% | 5.18% | $183.33B | Nov 13, 2025 | ▼ 312.7K |
SACHEM HEAD CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 8.96M | 3.71% | 3.71% | $131.35B | Nov 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 5.81M | 2.41% | 2.41% | $85.24B | Nov 12, 2025 | ▼ 99.4K |
NUVEEN, LLC biological products, (no diagnostic substances) | 5.72M | 2.37% | 2.37% | $83.92B | Nov 12, 2025 | ▲ 161.2K |
WESTFIELD CAPITAL MANAGEMENT CO LP biological products, (no diagnostic substances) | 5.11M | 2.11% | 2.11% | $74.87B | Nov 12, 2025 | NEW |
DIMENSIONAL FUND ADVISORS LP biological products, (no diagnostic substances) | 4.80M | 1.99% | 1.99% | $70.34B | Nov 12, 2025 | ▲ 35.2K |
AMERICAN CENTURY COMPANIES INC biological products, (no diagnostic substances) | 4.70M | 1.94% | 1.94% | $68.84B | Nov 12, 2025 | ▲ 84.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+10.90M shares5
New Positions
first time holders21
Decreased
−7.92M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.98M
+10.90M / −7.92M
Net new holders
+6
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ADMA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
1
Sell transactions
3.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Grossman Jerrold B director | May 27, 2026 | Purchase | 6,400 | $7.91 | $50.6K | 520.3K | Form 4 ↗ |
Grossman Jerrold B director | May 12, 2026 | Purchase | 12,500 | $8.01 | $100.1K | 513.9K | Form 4 ↗ |
Grossman Jerrold B director | May 11, 2026 | Purchase | 12,500 | $8.01 | $100.1K | 501.4K | Form 4 ↗ |
Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Apr 1, 2026 | Tax Withhold | 20,362 | $9.11 | $185.5K | 446.2K | Form 4 ↗ |
Guiheen Lawrence P. director | Mar 17, 2026 | Gift | 30,000 | — | — | 105.5K | Form 4 ↗ |
Guiheen Lawrence P. director | Mar 17, 2026 | Gift | 30,000 | — | — | 30.0K | Form 4 ↗ |
Grossman Adam S President and CEO | Mar 16, 2026 | Sale | 15,000 | $15.16 | $227.4K | 2.12M | Form 4 ↗ |
Grossman Adam S President and CEO | Mar 16, 2026 | Sale | 6,000 | $15.16 | $91.0K | 2.11M | Form 4 ↗ |
Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Mar 6, 2026 | Tax Withhold | 10,059 | $15.39 | $154.8K | 562.1K | Form 4 ↗ |
Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Mar 7, 2026 | Tax Withhold | 4,235 | $15.39 | $65.2K | 557.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
ADMA Biologics, Inc. (ADMA) is primarily owned by institutional investors, who hold approximately 94.6% of total shares outstanding. Company insiders own approximately 2.18%, while retail and public investors account for the remaining 3.19%.
The largest institutional shareholder of ADMA Biologics, Inc. is BLACKROCK, INC., holding approximately 35.63 million shares — equal to 14.75% of outstanding shares — as of September 30, 2025.
A total of 384 institutional investors currently hold ADMA stock, with a combined institutional value of approximately $3.28 billion as of the most recent 13F filing period.
Frequently asked questions
ADMA ownershipADMA Biologics, Inc. (ADMA) is primarily owned by institutional investors, who hold approximately 94.6% of shares. The largest shareholder is BLACKROCK, INC. with a 14.75% stake. Company insiders hold 2.18%. Data sourced from SEC Form 13F as of September 30, 2025.